Company · Healthcare
Every investor coverage indicates participated in a round New Zealand Clinical Research Group raised.
The transaction that ended New Zealand Clinical Research Group's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Advent | Acquisition | 19 Aug 2026 | - | healthcaredealflow.com, biospectrumasia.com, nzcr.co.nz, adventinternational.com, DealStreetAsia |
Companies New Zealand Clinical Research Group acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Tony Moffatt | CEO | biospectrumasia.com, adventinternational.com, DealStreetAsia |
Stories naming New Zealand Clinical Research Group. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Advent International is to take a majority holding in trans-Tasman clinical trials operator NZCR, whose existing backers, among them Waterman Capital, will keep a minority position, with a fourth-quarter close anticipated.
Also adventinternational.com·nzcr.co.nz·biospectrumasia.com·healthcaredealflow.com